Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
J Immunother
    August 2025
  1. BHATNAGAR S, Revuri V, Merali C, Wang B, et al
    A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary Adenocarcinoma.
    J Immunother. 2025 Aug 6. doi: 10.1097/CJI.0000000000000571.
    >> Share

    July 2025
  2. STEIMLE AK, Cho SY, Menon N, Jeraj R, et al
    ctDNA Dynamics Identifies Pseudoprogression in a Metastatic Melanoma Patient Treated With Nivolumab/Relatlimab.
    J Immunother. 2025 Jul 7. doi: 10.1097/CJI.0000000000000569.
    >> Share

    May 2025
  3. TANG J, Zhu S, Zhu L
    Integrated Single-Cell and Bulk RNA Sequencing Analysis Identifies a Regulated Cell Death-Related Gene Signature for Predicting Prognosis and Therapeutic Responses in Cutaneous Melanoma.
    J Immunother. 2025 May 30. doi: 10.1097/CJI.0000000000000564.
    >> Share

    April 2025
  4. SHAO YF, Baca Y, Hinton A, Xiu J, et al
    Immune Profiling of Uveal Melanoma Liver Metastases and Response to Checkpoint Inhibitors.
    J Immunother. 2025 Apr 15. doi: 10.1097/CJI.0000000000000558.
    >> Share

    November 2024
  5. FAN C, Li Y, Jiang A, Zhao R, et al
    Machine Learning-enhanced Signature of Metastasis-related T Cell Marker Genes for Predicting Overall Survival in Malignant Melanoma.
    J Immunother. 2024 Nov 7. doi: 10.1097/CJI.0000000000000544.
    >> Share

    October 2024
  6. FESSLER K, Zhang J, Sandhu AK, Hui Y, et al
    Brief Communication: Combination of an MIP3alpha-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNalpha and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model.
    J Immunother. 2024 Oct 14. doi: 10.1097/CJI.0000000000000542.
    >> Share

    August 2024
  7. PERSA OD, Hassel JC, Steeb T, Erdmann M, et al
    Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary.
    J Immunother. 2024 Aug 29. doi: 10.1097/CJI.0000000000000537.
    >> Share

    July 2024
  8. WANG ZZ, Yao GT, Wang LZ, Zhu YJ, et al
    Increased Expression and Prognostic Significance of BYSL in Melanoma.
    J Immunother. 2024 Jul 9. doi: 10.1097/CJI.0000000000000530.
    >> Share

    February 2024
  9. BASIR S, Bosiers J, Westgeest HM, Yick DCY, et al
    Bronchiolitis after Combination Immunotherapy With Ipilimumab and Nivolumab in a Melanoma Patient.
    J Immunother. 2024 Feb 27. doi: 10.1097/CJI.0000000000000509.
    >> Share

  10. ARAK H, Erkilic S, Yaslikaya S, Eylemer Mocan E, et al
    The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
    J Immunother. 2024 Feb 7. doi: 10.1097/CJI.0000000000000508.
    >> Share

  11. DE JOODE K, Mora AR, van Schaik RHN, Zippelius A, et al
    Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
    J Immunother. 2024 Feb 6. doi: 10.1097/CJI.0000000000000506.
    >> Share

    September 2023
  12. D'ANNIBALLE VM, Huang MN, Lueck BD, Nicholson LT, et al
    Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model.
    J Immunother. 2023 Sep 20. doi: 10.1097/CJI.0000000000000487.
    >> Share

  13. SCHON V, Stocker D, Jungst C, Dummer R, et al
    Immune-Related Sclerosing Cholangitis and Subsequent Pyogenic Liver Abscesses in Two Patients With Melanoma Treated by Triplet Therapy: A Case Report.
    J Immunother. 2023 Sep 19. doi: 10.1097/CJI.0000000000000486.
    >> Share

    June 2023
  14. BUCHBINDER EI, Pfaff KL, Turner MM, Manos M, et al
    Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy.
    J Immunother. 2023;46:192-196.
    >> Share

    May 2023
  15. ZHANG L, Cao L, Li S, Wang L, et al
    Biologically Interpretable Deep Learning To Predict Response to Immunotherapy In Advanced Melanoma Using Mutations and Copy Number Variations.
    J Immunother. 2023 May 24. doi: 10.1097/CJI.0000000000000475.
    >> Share

    April 2023
  16. VAN ZEIJL MCT, van Breeschoten J, de Wreede LC, Wouters MWJM, et al
    Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
    J Immunother. 2023 Apr 28. doi: 10.1097/CJI.0000000000000468.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016